Publication: A reduced curcuminoid analog as a novel inducer of fetal hemoglobin
10
Issued Date
2013-03-01
Resource Type
ISSN
14320584
09395555
09395555
Other identifier(s)
2-s2.0-84873987312
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of Hematology. Vol.92, No.3 (2013), 379-386
Suggested Citation
Nattawara Chaneiam, Chatchawan Changtam, Thongperm Mungkongdee, Umaporn Suthatvoravut, Pranee Winichagoon, Jim Vadolas, Apichart Suksamrarn, Suthat Fucharoen, Saovaros Svasti A reduced curcuminoid analog as a novel inducer of fetal hemoglobin. Annals of Hematology. Vol.92, No.3 (2013), 379-386. doi:10.1007/s00277-012-1604-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/32465
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A reduced curcuminoid analog as a novel inducer of fetal hemoglobin
Other Contributor(s)
Abstract
Thalassemia is an inherited disorder of hemoglobin molecules that is characterized by an imbalance of α- and β-globin chain synthesis. Accumulation of unbound α-globin chains in erythroid cells is the major cause of pathology in β-thalassemia. Stimulation of γ-globin production can ameliorate disease severity as it combines with the α-globin to form fetal hemoglobin. We examined γ-globin-inducing effect of curcuminoids extracted from Curcuma longa L. and their metabolite reduced forms in erythroid leukemia K562 and human primary erythroid precursor cells. The results showed that curcuminoid compounds, especially bisdemethoxycurcumin are potential γ-globin enhancers. We also demonstrated that its reduced analog, hexahydrobisdemethoxycurcumin (HHBDMC), is most effective and leads to induction of γ-globin mRNA and HbF in primary erythroid precursor cells for 3.6 ± 0.4- and 2.0 ± 0.4-folds, respectively. This suggested that HHBDMC is the potential agent to be developed as a new therapeutic drug for β-thalassemia and related β-hemoglobinopathies. © 2012 Springer-Verlag Berlin Heidelberg.